IRIS
REFINI, ROSA METELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.884
EU - Europa 6.228
AS - Asia 2.872
SA - Sud America 419
Continente sconosciuto - Info sul continente non disponibili 220
AF - Africa 117
OC - Oceania 8
AN - Antartide 1
Totale 16.749
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.755
IT - Italia 1.671
RU - Federazione Russa 1.136
GB - Regno Unito 1.111
CN - Cina 892
SG - Singapore 851
IE - Irlanda 708
SE - Svezia 387
VN - Vietnam 385
BR - Brasile 337
DE - Germania 276
UA - Ucraina 270
FR - Francia 265
HK - Hong Kong 235
FI - Finlandia 155
BD - Bangladesh 83
IN - India 82
KR - Corea 71
TR - Turchia 71
ES - Italia 69
CA - Canada 66
ZA - Sudafrica 53
MX - Messico 40
PL - Polonia 34
IQ - Iraq 32
BE - Belgio 30
JP - Giappone 27
AR - Argentina 26
CZ - Repubblica Ceca 26
PK - Pakistan 20
NL - Olanda 17
ID - Indonesia 16
MA - Marocco 16
EC - Ecuador 15
NG - Nigeria 14
AT - Austria 13
CI - Costa d'Avorio 12
IR - Iran 12
LT - Lituania 12
PH - Filippine 12
SA - Arabia Saudita 12
CL - Cile 10
AZ - Azerbaigian 9
UZ - Uzbekistan 9
JO - Giordania 8
PT - Portogallo 8
VE - Venezuela 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
IL - Israele 6
LB - Libano 6
UY - Uruguay 6
DK - Danimarca 5
DZ - Algeria 5
KZ - Kazakistan 5
PE - Perù 5
RO - Romania 5
TT - Trinidad e Tobago 5
CH - Svizzera 4
CO - Colombia 4
HN - Honduras 4
HU - Ungheria 4
JM - Giamaica 4
KE - Kenya 4
NP - Nepal 4
PY - Paraguay 4
SN - Senegal 4
AL - Albania 3
BG - Bulgaria 3
BO - Bolivia 3
EG - Egitto 3
EU - Europa 3
GR - Grecia 3
IS - Islanda 3
KG - Kirghizistan 3
MY - Malesia 3
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
LV - Lettonia 2
NO - Norvegia 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TW - Taiwan 2
AG - Antigua e Barbuda 1
AQ - Antartide 1
BH - Bahrain 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
GY - Guiana 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
Totale 16.525
Salva come PNG Salva come JPEG
Città #
Southend 977
Dallas 722
Dublin 700
Fairfield 675
Ashburn 548
Singapore 509
Chandler 391
Santa Clara 354
Moscow 321
San Jose 305
Woodbridge 303
Seattle 283
Beijing 279
Houston 261
Siena 234
Wilmington 232
Jacksonville 222
Hong Kong 218
Cambridge 214
Milan 205
Ann Arbor 155
New York 120
Princeton 117
Ho Chi Minh City 116
Council Bluffs 101
Dearborn 96
Los Angeles 95
Helsinki 90
Hanoi 87
Hefei 84
The Dalles 73
Munich 70
Rome 70
Seoul 69
Lastra a Signa 68
Lauterbourg 66
Florence 61
Nanjing 60
Boardman 53
Johannesburg 49
Gavirate 48
San Mateo 45
Izmir 44
Málaga 43
Buffalo 39
Shanghai 39
São Paulo 37
San Diego 35
Columbus 33
Catania 32
Dong Ket 32
Nanchang 32
Orem 29
Warsaw 29
Chennai 27
London 26
Changsha 24
Turku 24
Frankfurt am Main 23
Fremont 23
Tokyo 23
Montreal 22
Da Nang 20
Chicago 19
Figino 19
Haiphong 19
Atlanta 18
Brussels 18
Boston 16
Düsseldorf 16
Guangzhou 16
Hebei 16
Manchester 16
Redondo Beach 16
Turin 15
Baghdad 14
Brooklyn 14
Poplar 14
San Francisco 14
Shenyang 14
Stockholm 14
Toronto 14
Brno 13
Hangzhou 13
Kunming 13
Lahore 13
Mexico City 13
Phoenix 13
Abidjan 12
Abuja 12
Dhaka 12
Menlo Park 12
Norwalk 12
Denver 11
Jakarta 11
Olomouc 11
Prato 11
Bengaluru 10
Jiaxing 10
Rio de Janeiro 10
Totale 10.896
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.057
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 366
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 356
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 355
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 310
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 305
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 289
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 284
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 282
Exhaled nitric oxide in interstitial lung diseases 276
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 271
Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model 264
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 263
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 262
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 261
Different effects of inhaled aspirinlike drugs on allergen-induced early and late asthmatic responses 258
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 258
Prognostic bioindicators in severe COVID-19 patients 257
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 256
Posttransplant solid organ malignancies in lung transplant recipients: A single-center experience and review of the literature 253
Omalizumab treatment in Samter's triad: case series and review of the literature 250
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 249
Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma 245
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 243
A functional proteomics approach to the comprehension of sarcoidosis 238
Could NSAIDs have a role as antiasthmatic agents? 235
Pirfenidone therapy for familial pulmonary fibrosis: a real-life study. 232
NK and NKT-like cells in granulomatous and fibrotic lung diseases 230
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 230
Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent 227
Attenuation of aspirin-induced bronchoconstriction by sodium cromoglycate and nedocromil sodium 220
Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial 220
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 218
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 216
Chitotriosidase: a sensitive biomarker of sarcoidosis 215
Coronavirus HKU 1 infection with bronchiolitis, pericardial effusion and acute respiratory failure in obese adult female 215
Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin 213
Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions 212
Serum analysis of coagulation factors in IPF and NSIP 207
Postoperative acute kidney injury in lung transplant recipients 205
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 202
Proteomic investigation of pulmonary sarcoidosis 200
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 198
Inhaled loop diuretics as potential new anti-asthmatic drugs 197
IPF mortality in waiting list for lung transplantation 192
Helicobacter pylori Infection Does Not Impact on Lung Transplant Outcome 192
Steroid-sparing effect of inhaled lysine acetylsalicylate and furosemide in high-dose beclomethasone-dependent asthma 187
Mortalità in lista per trapianto di polmone in pazienti affetti da fibrosi polmonare idiopatica 182
Time-limited protective effect of inhaled frusemide against aspirin-induced bronchoconstriction in aspirin-sensitive asthmatics 178
Chitotriosidase analysis in bronchoalveolar lavage of patients with sarcoidosis. 177
Familial pulmonary fibrosis: Clinical-functional and radiological features 171
P172 Pulmonary Hypertension In Ipf: Utility Of Hrct 171
Immunologic responses to antifibrotic treatment in IPF patients 169
New concepts in the pathogenesis of sarcoidosis 168
Exhaled carbon monoxide in sarcoidosis 167
Exploring the interaction between fractional exhaled nitric oxide and biologic treatment in severe asthma: a systematic review 166
Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction 163
Helicobacter pylori seroprevalence in patients with idiopathic pulmonary fibrosis 160
Immune checkpoint analysis of T-cell responses to pp65 and IE-1 antigens in end-stage lung diseases 154
Protective activity of inhaled nonsteroidal antiinflammatory drugs on bronchial responsiveness to ultrasonically nebulized water 151
Utility of spiral CAT scan in the follow-up of patients with pulmonary Largerhans cell histiocytosis 150
Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility 150
Valutazione dell'ossido nitrico nell'esalato delle polmoniti interstiziali idiopatiche 148
The effectiveness of nintedanib in patients with idiopathic pulmonary fibrosis, familial pulmonary fibrosis and progressive fibrosing interstitial lung diseases: a real-world study 145
null 143
Potentiation of the antireactive, antiasthmatic effect of inhaled furosemide by inhaled lysine acetylsalicylate 141
Exhaled nitric oxide and carbon monoxide in lung transplanted patients 140
null 121
Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP 118
Nintedanib in Idiopathic Pulmonary Fibrosis: a single-centre real-life experience 111
Human chitotriosidase analysis: a reliable biomarker of sarcoidosis severity 106
null 106
Calgranulin B/S100A9 and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP 104
Serum and BAL levels of KL6 in chronic hypersensitivity pneumonitis Serum and BAL levels of KL6 in chronic hypersensitivity pneumonitis 99
Erratum: Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis (Respiratory Research (2020) 21 (6) DOI: 10.1186/s12931-019-1263-z) 91
Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis 78
null 63
Esperienza in real-life della terapia con Pirfenidone in pazienti affetti da IPF. 47
Esperienza in real-life della terapia con Pirfenidone in pazienti affetti da IPF. 41
The value of urinary calcium as biomarker in chronic sarcoidosis 37
Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy 36
Evaluation of exhaled nitric oxide in idiopathic interstitial lung diseases 26
Totale 16.749
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.176
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.176
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022973 0 132 79 91 52 30 49 43 34 108 149 206
2022/20231.328 85 137 159 167 131 241 50 102 137 57 38 24
2023/20241.200 39 21 104 54 59 306 399 36 8 38 21 115
2024/20252.156 135 99 246 77 297 144 109 103 147 103 237 459
2025/20265.329 377 604 599 658 1.113 208 662 127 148 273 163 397
2026/2027202 166 36 0 0 0 0 0 0 0 0 0 0
Totale 16.749